Literature DB >> 4117647

[Modern treatment of parkinsonism].

W Birkmayer, E Neumayer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4117647

Source DB:  PubMed          Journal:  Z Neurol        ISSN: 0012-1037


× No keyword cloud information.
  75 in total

1.  [HEAT REGULATION IN POSTENCEPHALITIC PARKINSONISM].

Authors:  W BIRKMAYER; E NEUMAYER
Journal:  Nervenarzt       Date:  1963-08       Impact factor: 1.214

2.  [Features of medical therapy of Parkinson's syndrome].

Authors:  W BIRKMAYER; M MENTASTI
Journal:  Wien Klin Wochenschr       Date:  1962-10-12       Impact factor: 1.704

Review 3.  Theoretical implications of the use of L-dopa in parkinsonism. A review.

Authors:  H Klawans; M M Ilahi; D Shenker
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

4.  L-dopa plus decarboxylase inhibitor in depression.

Authors:  N Matussek; O Benkert; K Schneider; H Otten; H Pohlmeier
Journal:  Lancet       Date:  1970-09-26       Impact factor: 79.321

5.  Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta-hydroxylase, affects serotonin and noradrenaline.

Authors:  H Hidaka
Journal:  Nature       Date:  1971-05-07       Impact factor: 49.962

6.  [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].

Authors:  W Danielczyk; J J Korten
Journal:  Med Monatsschr       Date:  1971-10

7.  Parkinsonism, L-dopa and mental depression.

Authors:  M Cherington
Journal:  J Am Geriatr Soc       Date:  1970-07       Impact factor: 5.562

8.  The activating effect of L-dopa treatment on sexual functions and its experimental background.

Authors:  M Hyyppä; U K Rinne; V Sonninen
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

9.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

10.  Sexual behavior during L-dopa treatment for Parkinsonism.

Authors:  M B Bowers; M Van Woert; L Davis
Journal:  Am J Psychiatry       Date:  1971-06       Impact factor: 18.112

View more
  14 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

3.  Impairment of motor planning in patients with Parkinson's disease: evidence from ideomotor apraxia testing.

Authors:  G Goldenberg; A Wimmer; E Auff; G Schnaberth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

4.  Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.

Authors:  W Birkmayer; W Danielczyk; E Neumayer; P Riederer
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

5.  L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].

Authors:  L Ambrozi; W Birkmayer; P Riederer; M B Youdim
Journal:  Br J Pharmacol       Date:  1976-11       Impact factor: 8.739

Review 6.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

7.  Long term treatment with L-deprenyl.

Authors:  W Birkmayer
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

8.  Hallucinations in Parkinson disease: neuropsychological study.

Authors:  G Meco; V Bonifati; G Cusimano; E Fabrizio; N Vanacore
Journal:  Ital J Neurol Sci       Date:  1990-08

9.  DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.

Authors:  W Birkmayer; G Birkmayer; H Lechner; P Riederer
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

Review 10.  Is NADH effective in the treatment of Parkinson's disease?

Authors:  R H Swerdlow
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.